Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Shannon C. Leonard"'
Autor:
Bart S. Hendriks, Thomas J. Wickham, Victor Moyo, Dmitri B. Kirpotin, Stephanie J. Blocker, Elena Geretti, Shannon C. Leonard, Daniel F. Gaddy, Karen Campbell, Pamela N. Munster, Patricia M. LoRusso, Cynthia X. Ma, Ian Krop, Kathy D. Miller, Barry A. Siegel, Anthony F. Shields, Helen Lee
Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an expl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f02abcc0f9da3083a31a91ce975db7
https://doi.org/10.1158/1078-0432.c.6527147
https://doi.org/10.1158/1078-0432.c.6527147
Autor:
Bart S. Hendriks, Thomas J. Wickham, Victor Moyo, Dmitri B. Kirpotin, Stephanie J. Blocker, Elena Geretti, Shannon C. Leonard, Daniel F. Gaddy, Karen Campbell, Pamela N. Munster, Patricia M. LoRusso, Cynthia X. Ma, Ian Krop, Kathy D. Miller, Barry A. Siegel, Anthony F. Shields, Helen Lee
Fig. S1. MM-302 tumor deposition in preclinical xenografts as a function of HER2 expression. Fig. S2. Preclinical assessment of minimum 64Cu-MM-302 tumor delivery for anti-tumor activity. Fig. S3. Maximum intensity projection images of selected patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0232c3d75a5d2bec8207e23a720c3cc2
https://doi.org/10.1158/1078-0432.22469117
https://doi.org/10.1158/1078-0432.22469117
Autor:
Bart S. Hendriks, Thomas J. Wickham, Elena Geretti, Shannon C. Leonard, Christopher W. Espelin
Trastuzumab is the standard of care for HER2-positive breast cancer patients, markedly improving disease-free and overall survival. Combined with chemotherapy, it enhances patient outcomes, but cardiotoxicity due to the trastuzumab treatment poses a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40abba3c3e60e12deea8359e4c7db1ec
https://doi.org/10.1158/0008-5472.c.6507579.v1
https://doi.org/10.1158/0008-5472.c.6507579.v1
Autor:
Bart S. Hendriks, Thomas J. Wickham, Elena Geretti, Shannon C. Leonard, Christopher W. Espelin
Supp. Figure 1 MM-302 and trastuzumab co-localize in BT474-M3 xenograft tumors. Supp. Figure 2 In vivo deposition of MM-302 is specifically increased by trastuzumab or T-DM1. Supp. Figure 3 Pharmacokinetics (PK) of MM-302 remains the same with or wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50eaa7d8fc7fcc80c1aa830c610cccd7
https://doi.org/10.1158/0008-5472.22408632
https://doi.org/10.1158/0008-5472.22408632
Autor:
Bart S. Hendriks, Thomas J. Wickham, Elena Geretti, Shannon C. Leonard, Christopher W. Espelin
Supp. Figure 1 MM-302 and trastuzumab co-localize in BT474-M3 xenograft tumors. Supp. Figure 2 In vivo deposition of MM-302 is specifically increased by trastuzumab or T-DM1. Supp. Figure 3 Pharmacokinetics (PK) of MM-302 remains the same with or wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d30438dcecd454b273328c216df90c5
https://doi.org/10.1158/0008-5472.22408629.v1
https://doi.org/10.1158/0008-5472.22408629.v1
Autor:
Shannon C. Leonard, Maegan Hoover, Thomas Wickham, Shannon McArdel, Sivan Elloul, Laurence A. Turka, Arjun Bollampalli, Zafira Castaño, Nicholas Bayhi, Christopher L. Carpenter, Enping Hong, Douglas C. McLaughlin, Kelvin Muriuki, Sneha Pawar, Jennifer Mellen, Anne-Sophie Dugast
Publikováno v:
Cancer Immunology, Immunotherapy
Recombinant agonists that activate co-stimulatory and cytokine receptors have shown limited clinical anticancer utility, potentially due to narrow therapeutic windows, the need for coordinated activation of co-stimulatory and cytokine pathways and th
Autor:
Sivan Elloul, Anne-Sophie Dugast, Shannon McArdel, Ryan Pepi, Maegan Hoover, Laurence A. Turka, Enping Hong, Alex Nanna, Shannon C. Leonard, Arjun Bollampalli, Zafira Castaño
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAgonist antibodies and recombinant cytokines have had limited success in the clinic due to three factors: severe toxicity leading to a narrow therapeutic index, the diminished activity of an agonistic antibody compared with natural ligand,
Autor:
Silvia Coma, Tom Wickham, Joe Reynolds, Christopher W. Espelin, Elena Geretti, Nancy Dumont, Shannon C. Leonard, Z Koncki, István Molnár
Publikováno v:
Cancer Research. 77:P3-06
This abstract was withdrawn by the authors.
Autor:
Jinzi Zheng, Helen Lee, Nancy Dumont, Victor Moyo, Raquel De Souza, Daniel F. Gaddy, David A. Jaffray, Christopher W. Espelin, Elena Geretti, Ulrik B. Nielsen, Thomas Wickham, Bart S. Hendriks, Shannon C. Leonard
Publikováno v:
Molecular Cancer Therapeutics. 14:2060-2071
Given the bulky nature of nanotherapeutics relative to small molecules, it is hypothesized that effective tumor delivery and penetration are critical barriers to their clinical activity. HER2-targeted PEGylated liposomal doxorubicin (MM-302, HER2-tPL
Autor:
Daniel F. Gaddy, Christopher W. Espelin, Nancy Dumont, Shannon C. Leonard, Elena Geretti, Bart S. Hendriks, Thomas Wickham
Publikováno v:
Cancer Research. 75:P6-11
MM-302, HER2-targeted PEGylated liposomal doxorubicin, is a liposomal antibody drug conjugate designed to target doxorubicin to HER2-overexpressing cancer cells, while limiting uptake into non-target cells. Effective tumor delivery and penetration ar